logo
  

Carnival Says Princess Cruises Plans To Resume Cruising In United States In Fall 2021

Carnival plc (CCL,CUK,CCL.L), on Friday, said its Princess Cruises continues plan to return to service in the United States sailing from Los Angeles, San Francisco, and Ft. Lauderdale this fall, following collaboration with government officials, and evolving guidance from the U.S. Centers for Disease Control and Prevention or CDC.

Starting between September 25 and November 28, 2021, cruises onboard eight Princess MedallionClass ships would once again take guests to the Caribbean, Panama Canal, Mexico, Hawaii, and the California Coast.

The company noted that Princess cruises sailing through 2021 are available for guests who have received their final dose of an approved COVID-19 vaccine at least 14 days prior to the beginning of the cruise and have proof of vaccination. Crew vaccinations would be in accordance with CDC guidelines, the company added.

"As we continue our return to service, it is a thrill for us to be able to bring more cruise vacation options to our travel-starved guests," said Jan Swartz, Princess Cruises president. "We appreciate the support of government and port officials who we worked closely with to make these travel opportunities available, in a thoughtful and safe way, for our guests."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Flavor maker McCormick & Co., Inc. is recalling certain McCormick and Frank's brand seasoning products citing possible salmonella risk, the U.S. Food and Drug Administration said. The recall involves McCormick Perfect Pinch Italian Seasoning, McCormick Culinary Italian Seasoning and Frank's RedHot Buffalo Ranch Seasoning. Drug major Pfizer Inc. raised Wednesday its outlook for fiscal 2021 earnings and revenues following strong second quarter results that exceeded market estimates. According to the company, the upward revision in full-year outlook, for the second quarter in a row, reflects its updated expectations for contributions to 2021 performance from both BNT162b2, the Pfizer-BioNTech SE COVID-19 vaccine. While reporting financial results for the second quarter on Wednesday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) reaffirmed its adjusted earnings and revenue growth guidance for the full-year 2021. For fiscal 2021, the company now projects earnings in a range of $3.18 to $3.38 per share,...
Follow RTT